Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve a new way of starting treatment with its drug Tremfya (guselkumab) for ...
Hosted on MSN
Johnson & Johnson Seeks FDA Nod for TREMFYA® Label Update Following Psoriatic Arthritis Trial Success
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration, seeking approval to update the labeling for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback